ライフサイエンスコーパス: FGF21

1 tabolic hormone fibroblast growth factor 21 (FGF21).

2 subsequent hepatic expression of the hormone FGF21.

3 on a recently identified natural substrate, FGF21.

4 , via a heart-brown fat cross-talk involving FGF21.

5 uction in hepatic Fgf21 mRNA and circulating FGF21.

6 chastically increasing hepatic expression of Fgf21.

7 FA flux from adipose tissue to the liver via FGF21.

8 he enzyme that cleaves and inactivates human FGF21.

9 circulating levels and hepatic expression of FGF21.

10 co-receptor, which suggests a resistance to Fgf21.

11 ted by using a neutralizing antibody against FGF21.

12 th and mediated by the liver-derived hormone FGF21.

13 lasma levels of fibroblast growth factor 21 (FGF21), a hepatokine known to increase systemic insulin

14 togenic hormone fibroblast growth factor 21 (FGF21), a member of the endocrine FGF subfamily, is expr

15 Fibroblast growth factor 21 (FGF21), a peptide hormone with pleiotropic effects on ca

16 size at birth but show a marked increase in FGF21 accompanied by reduced body mass, shortened body l

17 We also examined the physiological site of FGF21 action during cold exposure by impairing FGF21 sig

18 Our study extends the work of the FGF21 actions on the neurocontrol of blood pressure regu

19 -species differences or complex interplay of FGF21 activity and counter-regulatory mechanisms.

20 therapeutic approach to increase endogenous FGF21 activity for the treatment of obesity, type 2 diab

21 induces muscle atrophy, but via secretion of FGF21 acts distally to modulate whole-body metabolism.

22 the liver (FGF21 LivKO) or adipose tissues (FGF21 AdipoKO), we performed a series of cold exposure s

23 tyrate (3-HIB), fibroblast growth factor 21 (FGF21), adiponectin, and nonesterified fatty acids (NEFA

24 rate of glucose disposal, and plasma 3-HIB, FGF21, adiponectin, and NEFA concentrations, under basal

25 In addition, we report that FGF21 administration does not alter protein preference,

26 Subjects with smaller increases in FGF21 after the low-protein high-fat diet gained more we

27 eases in plasma fibroblast growth factor 21 (FGF21) after 24-h fasting and after COLD were highly cor

28 sociated genes (fibroblast growth factor 21 [FGF21], alphaKlotho, soluble form of mouse transforming

29 FGF21 also regulates fatty acid metabolism in mice consu

30 e treated 6-week-old Bscl2(-/-) mice with an FGF21 analog (LY2405319) for a period of 28 days.

31 PEGylated human fibroblast growth factor 21 (FGF21) analogue, has previously been shown to improve ma

32 s showing an association between circulating FGF21 and diet-related EE in humans.

33 ide association study (GWAS) for circulating FGF21 and FGF23 concentrations to identify their genetic

34 de polymorphisms (SNPs) with log-transformed FGF21 and FGF23 serum concentrations adjusted for age, s

35 isms underlying the binding specificities of FGF21 and FGF23 to beta-Klotho or alpha-Klotho, respecti

36 ired for the high-affinity binding of FGF19, FGF21 and FGF23 to their cognate FGF receptors (FGFRs).

37 or protein intake, and corroborating earlier FGF21 and FTO findings.

38 ed stress response associated with increased FGF21 and GDF15 expression enhances the metabolism modul

39 xpression of the genes encoding the myokines FGF21 and GDF15.

40 this study, we assessed the tissue source of FGF21 and its site of action to regulate core body tempe

41 owever, FGF21 was not elevated in serum, and FGF21 and UCP1 mRNAs were not induced in liver or brown

42 lpha (PGC-1alpha) reduced hepatic and plasma FGF21 and white adipocyte tissue-specific GLUT4 expressi

43 JNK) inhibiting fibroblast growth factor 21 (FGF21) and activating Bmal1 expression in the hepatocyte

44 serum levels of fibroblast growth factor 21 (FGF21), and activation of signaling pathways in adipose

45 ression, as sites of ligand action by FGF19, FGF21, and FGF1 in the mammalian brain remains unresolve

46 growth factor (FGF) family designated FGF19, FGF21, and FGF23 mediate their pleiotropic cellular effe

47 osclerosis and/or cardiovascular risk (CCL7, FGF21, and IGFBP1) proteins, the blood profiles of patie

48 However, the interplay between adiponectin, FGF21, and resistin signaling pathways during the onset

49 Unbiased gene profiling studies revealed Fgf21 as a key negatively regulated Dnmt3a target gene i

50 We therefore establish Fgf21 as a novel gene target of Fenretinide signalling v

51 fied betaKlotho, an essential coreceptor for FGF21, as a direct target gene of Rev-erbalpha in white

52 ward regulatory loop caused by JNK-regulated FGF21 autocrine signaling in adipocytes that promotes in

53 during fasting via GRalpha and the PPARalpha-FGF21 axis that reduces fat burning.

54 gh an NEAA insufficiency-induced liver NUPR1/FGF21 axis.

55 rtially by modulating the hepatic PGC-1alpha-FGF21 axis.

56 high in fat (46%), with larger increases in FGF21 being associated with greater increases in 24-h EE

57 As the critical co-receptor of FGF21, beta-klotho (klb) significantly expressed on the

58 ry, activation of hepatic AMPK/sirtuin-1 and FGF21/beta-klotho signaling pathways combined with down-

59 s such as HDL cholesterol, free fatty acids, FGF21, bilirubin, and lactate depend on the microbiome.

60 nuated the induction of Fgf21 expression and FGF21 biosynthesis in fasted mice.

61 f b-cell translocation gene 2 (BTG2)-induced FGF21 biosynthesis.

62 The expression levels of hepatic Fgf21, Btg2, and Klf15, and the production of serum FGF2

63 tein restriction, and requires both UCP1 and FGF21 but is independent of changes in food intake.

64 s may also upregulate SIRT1, PGC-1alpha, and FGF21 by a direct effect on the heart.

65 Supplementation of FGF21 by administration of an FGF21-expressing adeno-ass

66 ic and diet-induced mouse models of obesity, FGF21 can attenuate obesity-associated morbidities.

67 Consistent with this, Fgf21 can rescue Dnmt3a-mediated insulin resistance, and

68 Paradoxically, these Fgf21(-/-) CKD mice escaped several complications observ

69 ype mice and restored the survival period in Fgf21(-/-) CKD mice.

70 s system (CNS) using genetic ablation of the FGF21 co-receptor beta-klotho in adipose tissues (KLB Ad

71 Plasma FGF21 concentration consistently increased by threefold

72 P-mediated decrease in 3-HIB and increase in FGF21 concentration in plasma.

73 micromol/L) and the grand median [quartiles] FGF21 concentration increased (from 178 [116, 217] to 50

74 We assessed the changes in plasma FGF21 concentrations after 24 h of seven dietary interve

75 Serum FGF21 concentrations increased up to 44-fold during over

76 low-protein diet and measurements of plasma FGF21 concentrations.

77 Fibroblast growth factor 21 (FGF21) controls metabolic organ homeostasis and eating/d

78 < .0002; for PP diet P < .0002); decrease in FGF21 correlated with loss of hepatic fat.

79 FGF21 could thus be tracked along the endocytotic pathwa

80 d to sKLB and demonstrate that FGF19(CT) and FGF21(CT) bind to the same binding site on sKLB, via a m

81 ellular stimulatory activities of FGF19(CT,) FGF21(CT), and a variety of chimeric mutants to cells ex

82 Serum level of FGF21 decreased by 50% in each group (for AP diet P < .0

83 However, the FGF21-dependent increase in UCP1 and energy expenditure

84 energy expenditure and Ucp1 expression in an FGF21-dependent manner, neither LP diet nor the deletion

85 However, the physiological role of FGF21 during thermal challenges is not clear.

86 sed circulating fibroblast growth factor 21 (FGF21), elevated Fgf21 mRNA and protein solely in the he

87 owever, the neuron populations through which FGF21 elicits these effects are unknown.

88 Fibroblast Growth Factor 21 (FGF21) elicits an array of metabolic effects.

89 We found that only liver-derived FGF21 enters circulation during acute cold exposure and

90 FGF21 exerts profound metabolic effects in Siberian hams

91 culating adiponectin downstream of autocrine FGF21 expressed by adipocytes and upstream of endocrine

92 ssed by adipocytes and upstream of endocrine FGF21 expressed by hepatocytes.

93 lementation of FGF21 by administration of an FGF21-expressing adeno-associated virus vector recapitul

94 TCS-altered Fgf21 expression aligned with aberrant expression of gen

95 5 genes markedly attenuated the induction of Fgf21 expression and FGF21 biosynthesis in fasted mice.

96 nted high-carbohydrate, low-fat diet reduced FGF21 expression and plasma levels.

97 pharmacological activation of HRI increased Fgf21 expression and reduced lipid-induced hepatic steat

98 FGF21 expression and secretion as well as the associated

99 omeostasis, partly through the regulation of FGF21 expression and signaling.

100 Enhanced Fgf21 expression attenuated tunicamycin-induced endoplas

101 vo agonist activation of AHR reduces hepatic Fgf21 expression during a fast.

102 a small-molecule ISR activator that promoted Fgf21 expression in cell-based screens and by implicatio

103 Of note, increased Fgf21 expression in mice fed a high-fat diet or hepatocy

104 RNA analysis demonstrated that HRI regulates Fgf21 expression in primary hepatocytes.

105 We found that FGF21 expression in thymus declines with age and is indu

106 These results reveal that alcohol-induced FGF21 expression is a hepatic adaptive response to lipid

107 Here, we explore the role of AHR in hepatic Fgf21 expression through the use of a conditional, hepat

108 The link between the ISR and FGF21 expression was further reinforced by the identific

109 eased endogenous retinoic acid biosynthesis, Fgf21 expression was increased, whereas acute pharmacolo

110 Increased Fgf21 expression was observed in the livers of PPARbeta/

111 Hepa-1 cells ablates potent ER stress-driven Fgf21 expression, and pre-treatment with AHR antagonist

112 x) mice exhibit a 4-fold increase in hepatic Fgf21 expression, as well as elevated expression of the

113 glucose-, and ER stress-driven induction of FGF21 expression, indicating the effect is not mouse-spe

114 JNK activation, reduced Bmal1 and increased FGF21 expression, together with decreased lipogenesis in

115 D1 inhibition in primary hepatocytes induced FGF21 expression, which was repressed by treatment with

116 glucagon plus insulin to stimulate ATF4 and FGF21 expression.

117 ability of glucagon plus insulin to increase FGF21 expression.

118 he ability of glucagon to stimulate ATF4 and FGF21 expression.

119 ivity suppressed CDCA regulation of ATF4 and FGF21 expression.

120 TG2 are mediators of fasting-induced hepatic FGF21 expression.

121 c PPARalpha and fibroblast growth factor 21 (FGF21) expression and lower serum FGF21 levels, which ar

122 A low BCAA diet transiently induces FGF21 (fibroblast growth factor 21) and increases energy

123 ated receptor gamma coactivator 1-alpha) and FGF21 (fibroblast growth factor 21).

124 ion of the energy balance regulating hormone FGF21 (fibroblast growth factor 21).

125 nd secretion of fibroblast growth factor 21 (FGF21) from skeletal muscle, resulting in increased meta

126 Genetic gain of FGF21 function in mice protects against age-related thym

127 Conversely, loss of FGF21 function in middle-aged mice accelerated thymic ag

128 interacts with insulin to stimulate hepatic FGF21 gene expression.

129 n suppressed the ability of CDCA to increase FGF21 gene expression.

130 nism by which glucagon and insulin increased FGF21 gene transcription in primary hepatocyte cultures.

131 ription factor 4 (ATF4) binding sites in the FGF21 gene.

132 ate in the transcriptional regulation of the Fgf21 gene.

133 Fibroblast growth factor 21 (Fgf21) has emerged as a potential plasma marker to diagn

134 Fibroblast growth factor 21 (FGF21) has emerged as an important beneficial regulator

135 ess, suggesting that LP-induced increases in FGF21 impact metabolic but not thermogenic endpoints.

136 his was achieved by investigating effects of FGF21 in aged hamsters, which is associated with reduced

137 Fenretinide normalised elevated levels of FGF21 in both high-fat diet-induced obese mice and in ge

138 Thus, increased FGF21 in CKD can be viewed as a survival response at the

139 We sought to determine the role of FGF21 in hepatic steatosis in mice exposed to chronic al

140 and correlated negatively with expression of FGF21 in human adipose tissue.

141 Here we demonstrate that the actions of FGF21 in mouse adipose tissue, but not in liver, are mod

142 Administration of FGF21 in obese mice improves defective autophagy and hep

143 gh proteolytic cleavage of recombinant human FGF21 in preclinical species has been observed previousl

144 to examine the tissue specific induction of FGF21 in response to cold.

145 deletion of Fap stabilized recombinant human FGF21 in serum.

146 demonstrated a novel regulatory function of FGF21 in the baroreflex afferent pathway (the nucleus tr

147 the beneficial effects of a novel mimetic of FGF21 in the LD state are a consequence of increased adi

148 monstrate a previously unrecognized role for FGF21 in the maintenance of body temperature in response

149 f liver-derived fibroblast growth factor 21 (FGF21) in both lean and obese mice.

150 ulating hormone fibroblast growth factor 21 (FGF21) in the molecular mechanism regulating CYP3A4 expr

151 Btg2, and Klf15, and the production of serum FGF21 increased significantly in fasted and forskolin (F

152 ss by stimulating thermogenesis, but whether FGF21 increases energy expenditure (EE) in primates is u

153 ption factor (ATF) 4, which is essential for Fgf21-induced expression.

154 lance of lipid storage and metabolism due to FGF21-induced weight loss in the non-human primate model

155 adipose tissue of rhesus macaques following FGF21-induced weight loss.

156 Fibroblast growth factor 21 (FGF21) induces weight loss in mouse, monkey, and human s

157 essary and adequate for NUPR1 and subsequent FGF21 induction and secretion in hepatocytes in vitro an

158 FGF21 stimulation (causing varied levels of FGF21 induction) and Akt activation.

159 manner, neither LP diet nor the deletion of Fgf21 influenced sensitivity to acute cold stress.

160 Collectively, FGF21 integrates metabolic and immune systems to prevent

161 Collectively, these findings illustrate that FGF21 is a critical mediator of the effects of dietary M

162 FGF21 is a liver-derived hormone that induces responses

163 FGF21 is a stress-induced hormone with potent anti-obesi

164 FGF21 is an atypical member of the FGF family that funct

165 Fgf21(-/-) mice were used to test whether FGF21 is an essential mediator of the physiological effe

166 typically not expressed in skeletal muscle, FGF21 is induced in situations of muscle stress, particu

167 The biology of FGF21 is intrinsically complicated owing to its diverse

168 ntent in Fgf21(-/-) mice, demonstrating that Fgf21 is necessary for betaine's beneficial effects.

169 sly, the regulation of endogenously produced FGF21 is not well understood.

170 Here we show in mice that FGF21 is required to survive CKD but responsible for blo

171 work established that hepatic expression of FGF21 is robustly increased by MR.

172 In mice, FGF21 is thought to cause weight loss by stimulating the

173 Fibroblast growth factor 21 (FGF21) is a hepatokine that regulates glucose and lipid

174 Fibroblast growth factor 21 (FGF21) is a hormone that is vital for the regulation of

175 Fibroblast growth factor 21 (FGF21) is a peptide hormone that is synthesized by sever

176 Fibroblast growth factor 21 (FGF21) is an important regulator of the fasting and feed

177 Fibroblast growth factor-21 (FGF21) is closely related to various metabolic and cardi

178 These findings demonstrate that FGF21-JMJD3 signaling epigenetically links nutrient depr

179 Wildtype, Ucp1-KO and Fgf21-KO mice were placed on control and low protein (LP

180 y) showed suggestive associations with serum FGF21 level (P = 6.66 x 10(-7), 6.00 x 10(-7) and 6.11 x

181 FGF21 level appears to be a marker of metabolic improvem

182 The plasma Fgf21 level significantly correlated with intrahepatic t

183 NF-kB, reduced the hepatic and circulating FGF21 levels and altered the nonenzymatic (glutathione)

184 In CKD patients, high serum FGF21 levels are independently associated with decreased

185 The repression of FGF21 levels by Fenretinide occurs by reduced binding of

186 hibitor acutely increased circulating intact FGF21 levels in cynomolgus monkeys.

187 The up-regulated Fgf21 levels in NAFLD were implied to be a protective re

188 with both pericardial fat volume and plasma FGF21 levels measured at baseline.

189 However, higher FGF21 levels tended to be associated with less pericardi

190 We conducted the first GWAS of circulating FGF21 levels to date.

191 At the molecular level, elevated plasma Fgf21 levels were associated with dysregulated metabolic

192 linear mixed-effects model, higher baseline FGF21 levels were associated with higher pericardial fat

193 ting for confounding factors, ln-transformed FGF21 levels were positively associated with pericardial

194 Cross-sectionally, higher plasma FGF21 levels were significantly associated with higher p

195 te the longitudinal relationship of baseline FGF21 levels with pericardial fat accumulation.

196 s study, we investigated the relationship of FGF21 levels with pericardial fat volume in participants

197 volume per one SD increase in ln-transformed FGF21 levels), but less pericardial fat accumulation ove

198 lower per one SD increase in ln-transformed FGF21 levels).

199 xygen species damage, and elevated GDF15 and FGF21 levels, indicating metabolically dysfunctional fat

200 factor 21 (FGF21) expression and lower serum FGF21 levels, which are two proteins known to increase d

201 pharmacological retinoid treatment decreased FGF21 levels.

202 g triglyceride levels, glucose tolerance and FGF21 levels.

203 is a potential target for regulating hepatic FGF21 levels.

204 een circulating fibroblast growth factor 21 (FGF21) levels and pericardial fat volume in post-menopau

205 a benign stage of NAFLD, the elevated plasma Fgf21 likely indicated vulnerability to metabolic stress

206 ice lacking FGF21 specifically in the liver (FGF21 LivKO) or adipose tissues (FGF21 AdipoKO), we perf

207 sulin resistance, and DNA methylation at the FGF21 locus was elevated in human subjects with diabetes

208 In LD hamsters with increased adiposity, FGF21 lowered body weight as a result of both reduced da

209 When introduced with CKD, Fgf21(-/-) mice died earlier than wild-type mice.

210 Fgf21(-/-) mice were used to test whether FGF21 is an es

211 glucose homeostasis and liver fat content in Fgf21(-/-) mice, demonstrating that Fgf21 is necessary f

212 ivo insulin sensitivity in wild-type than in Fgf21(-/-) mice, particularly in heart and inguinal WAT.

213 a negative effect of MR on energy intake in Fgf21(-/-) mice.

214 sponse genes in liver was not compromised in Fgf21(-/-) mice.

215 in WAT and brown adipose tissue were lost in Fgf21(-/-) mice.

216 These findings suggest that 3-HIB and FGF21 might be involved in protein-mediated insulin resi

217 r study demonstrates the efficacy of a novel FGF21 mimetic in hamsters, but reveals attenuated effect

218 target genes, demonstrating its action as an FGF21 mimetic.

219 are phenocopied by an administration of the FGF21-mimetic antibody, consistent with its action to st

220 glucose tolerance and a reduction in hepatic Fgf21 mRNA and circulating FGF21.

221 ibroblast growth factor 21 (FGF21), elevated Fgf21 mRNA and protein solely in the heart, and upregula

222 A4 expression, circulating FGF21, or hepatic FGF21 mRNA levels were elevated.

223 ance, but these effects were not observed in Fgf21-null mice.

224 nimals with reduced adiposity, the effect of FGF21 on body weight, caloric intake and fat oxidation w

225 Chronic administration of recombinant FGF21 or engineered variants improves metabolic health i

226 ate genetic loci associated with circulating FGF21 or FGF23 levels were found.

227 Administration of recombinant FGF21 or transient hepatic overexpression of FGF21 resul

228 ls with lower CYP3A4 expression, circulating FGF21, or hepatic FGF21 mRNA levels were elevated.

229 Importantly, FGF21 overexpression reduced intrathymic lipid, increase

230 iver and Huh7 cells after FGF21 treatment or FGF21 overexpression.

231 d delineate the ever-expanding complexity of FGF21 physiology.

232 In the liver, FGF21 plays an important role in the regulation of fatty

233 However, roles that FGF21 plays in pathophysiology of CKD remains elusive.

234 using an adenoviral delivery system elevated FGF21 production by upregulating Klf15 transcription.

235 FGF21 production was impaired in CREBH-deficient mice, a

236 Similarly, the FSK-mediated induction of Fgf21 promoter activity was strikingly ablated by silenc

237 The Fgf21 promoter contains several putative dioxin response

238 concordant changes in DNA methylation at the Fgf21 promoter region.

239 precipitated with KLF15 and recruited by the Fgf21 promoter.

240 educed binding of RARalpha and Pol-II at the Fgf21 promoter.

241 An FGF21-PXR signaling pathway may be involved in decreased

242 nalyses of adipose tissue, expression of the FGF21 receptor cofactor beta-klotho was associated with

243 Moreover, the expressions of FGF21 receptors were aberrantly down-regulated in HFD ra

244 In conclusion, plasma levels of Fgf21 reflect liver fat accumulation and dysregulation o

245 In white adipose tissue (WAT), FGF21 regulates aspects of glucose metabolism, and in su

246 Fibroblast growth factor 21 (FGF21) regulates energy expenditure (EE) and influences

247 ptor (PPAR) beta/delta deficiency in hepatic FGF21 regulation.

248 Certain PPARalpha target genes such as Fgf21 remain repressed in the fetal liver and become PPA

249 Individuals with a blunted FGF21 response to a low-protein diet have a thrifty meta

250 FGF21 or transient hepatic overexpression of FGF21 resulted in reduced liver CYP3A4 luciferase report

251 xposed to alcohol received recombinant human FGF21 (rhFGF21) in the last 5 days.

252 ntraperitoneal infusion of recombinant human FGF21 (rhFGF21) on the dysregulated systolic blood press

253 associated with declining expression of Klb, Fgf21's crucial co-receptor, which suggests a resistance

254 ne (ARID3B/CYP1A1), carbohydrate metabolism (FGF21), schizophrenia (ZNF804A), and encoding enzymes im

255 lly, phosphorylation of JMJD3 at Thr-1044 by FGF21 signal-activated PKA increases its nuclear localiz

256 t SGLT2 inhibitors activate SIRT1/PGC-1alpha/FGF21 signaling and promote autophagy.

257 Targeting FGF21 signaling could be a novel treatment approach for

258 While FGF21 signaling directly to adipose tissues during cold

259 lish Rev-erbalpha as a specific modulator of FGF21 signaling in adipose tissue.

260 Specifically, FGF21 signaling in glutamatergic neurons is necessary fo

261 is dispensable for thermoregulation, central FGF21 signaling is necessary for maximal sympathetic dri

262 F21 action during cold exposure by impairing FGF21 signaling to adipose tissues or the central nervou

263 Upon FGF21 signaling, JMJD3 epigenetically upregulates global

264 ce through the impairment of adiponectin and FGF21 signaling.

265 (KLB AdipoKO) or pharmacological blockage of FGF21 signaling.

266 fasting-induced Fibroblast Growth Factor-21 (FGF21) signaling activates hepatic autophagy and lipid d

267 Fibroblast growth factor 21 (FGF21) signaling in the brain is necessary for the metab

268 Using mice lacking FGF21 specifically in the liver (FGF21 LivKO) or adipose

269 ating levels of fibroblast growth factor-21 (FGF21) start increasing in patients with chronic kidney

270 ecific pathways in the liver responsible for FGF21 stimulation (causing varied levels of FGF21 induct

271 cient mice, and adenoviral overexpression of FGF21 suppressed adipose tissue lipolysis and improved h

272 ssion, as well as elevated expression of the FGF21-target gene Igfbp1 Furthermore, in vivo agonist ac

273 ein solely in the heart, and upregulation of FGF21-target genes involved in thermogenesis and fatty a

274 E-cadherin and fibroblast growth factor 21 (FGF21), targets of sirtuin-1, and beta-klotho, which can

275 the hepatokine fibroblast growth factor 21 (FGF21) that regulates systemic metabolism.

276 n of a myokine, fibroblast growth factor 21 (FGF21), that stimulates energy consumption and prevents

277 twork genes, including Tfeb, Atg7, Atgl, and Fgf21, through demethylation of histone H3K27-me3, resul

278 r, the direct targets and mechanisms linking FGF21 to blood pressure control and hypertension are sti

279 effects were underpinned by the inability of FGF21 to increase the expression of key thermogenic gene

280 nstrate that glucagon plus insulin increases FGF21 transcription by stimulating ATF4 expression and t

281 lts also demonstrate that CDCA regulation of FGF21 transcription is mediated at least partially by an

282 ated that glucagon plus insulin induction of FGF21 transcription was conferred by two activating tran

283 to thermogenesis responded inconsistently to FGF21 treatment and weight loss.

284 Interestingly, FGF21 treatment exerted an antistress effect on SKD cell

285 Our data demonstrate that FGF21 treatment improves the metabolic profile of Bscl2(

286 FGF21 treatment increased adiponectin plasma levels and

287 observed in mouse liver and Huh7 cells after FGF21 treatment or FGF21 overexpression.

288 Notably, elevated plasma Fgf21 was associated with declining expression of Klb, F

289 Increased Fgf21 was associated with enhanced protein levels in the

290 oreover, Fenretinide-mediated suppression of FGF21 was independent of body weight loss or improved he

291 The fibroblast growth factor FGF21 was labeled with molecularly defined gold nanopart

292 However, FGF21 was not elevated in serum, and FGF21 and UCP1 mRNA

293 Strikingly, Fgf21 was the most downregulated hepatic gene.

294 bolic regulator fibroblast growth factor 21 (FGF21) was blunted by TCS.

295 Fibroblast growth factor 21 (FGF21) was shown to improve metabolic homeostasis, at le

296 Consequently, the effects of FGF21 were markedly enhanced in the white adipose tissue

297 ions, including fibroblast growth factor 21 (FGF21), were assessed at baseline, at wk 1, 3, and 6 of

298 e documented metabolic beneficial effects of FGF21, which include weight loss and improved glycemia.

299 s, the liver secretes the starvation hormone FGF21, which induces metabolic responses to fasting and

300 is activated by TG accumulation and induces FGF21, which suppresses adipose tissue lipolysis, amelio